tbuckley/cabot-search huggingface dataset:
An Outbreak of Sepsis Caused by Contaminated Intravenous Fluid: Clinical, Epidemiologic, and Laboratory Observations.
Authors: William Schaffner
Journal: Annals of Internal Medicine (1972)

Meeting Abstracts1 May 1972An Outbreak of Sepsis Caused by Contaminated Intravenous Fluid: Clinical, Epidemiologic, and Laboratory Observations.William Schaffner, M.D., F.A.C.P., S. K. Felts, M.D., M. A. Melly, Ph.D., M. G. Koenig, M.D., F.A.C.P.William Schaffner, M.D., F.A.C.P.Search for more papers by this author, S. K. Felts, M.D.Search for more papers by this author, M. A. Melly, Ph.D.Search for more papers by this author, M. G. Koenig, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-76-5-872_5 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe nationwide epidemic of sepsis caused by contaminated Abbott intravenous fluid has received wide publicity. Its effects on patients in Vanderbilt University Hospital, Nashville, Term., are presented. Twenty-nine patients had sepsis caused byEnterbacter cloacae,Herbicola lathyrigp., andPseudomonas stutzeri. These were uncommon pathogens prior to the outbreak. In four cases sepsis contributed to the patient's death. Patients ranged in age from 17 days to 86 years and were on all hospital services. The patients presented with hectic fever (93%), shaking chills (45%), and phlebitis at the infusion site (38%). Hypotension was less common (24%). Multiple positive blood cultures... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: William Schaffner, M.D., F.A.C.P.; S. K. Felts, M.D.; M. A. Melly, Ph.D.; M. G. Koenig, M.D., F.A.C.P.Affiliations: Nashville, Tenn. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 May 1972Volume 76, Issue 5Page: 872-873KeywordsBloodClinical epidemiologyClinical laboratoriesFeversHypotensionPathogensPseudomonasResearch laboratoriesSepsis ePublished: 1 December 2008 Issue Published: 1 May 1972 PDF downloadLoading ...
Influence of perfusate temperature on nasal potential difference
Authors: Inez Bronsveld, François Vermeulen, Dorotha Sands, Teresinha Leal, Anissa Leonard, Paola Melotti, Yasmin Yaakov, Roel de Nooijer, Kris De Boeck, Isabelle Sermet, Michael Wilschanski, Peter G. Middleton
Journal: European Respiratory Journal (2012)

Nasal potential difference (NPD) quantifies abnormal ion transport in cystic fibrosis. It has gained acceptance as an outcome measure for the investigation of new therapies. To quantify the effect of solution temperature on NPD, we first examined the effect of switching from room temperature (20-25°C) to warmed (32-37°C) solutions and vice versa during each perfusion step. Secondly, standard protocols were repeated at both temperatures in the same subjects. Changing solution temperature did not alter NPD during perfusion with Ringer's solution (<1 mV) (p>0.1). During perfusion with zero chloride solution, changing from room temperature to warmed solutions tended to decrease absolute NPD (i.e. it became less negative) by 0.9 mV (p>0.1); changing from warmed to room temperature increased NPD by 2.1 mV (p<0.05). During isoprenaline perfusion, changing from room temperature to warmed solutions increased NPD by 1.5 mV (p<0.01) and from warmed to room temperature decreased NPD by 1.4 mV (p<0.05). For full protocols at room temperature or warmed in the same subjects, mean values were similar (n = 24). During warmed perfusion, group results for total chloride response had a larger standard deviation. As this increased variability will probably decrease the power of trials, this study suggests that solutions at room temperature should be recommended for the measurement of NPD.
Attributes of Interventions That Stop Smoking-Reply
Authors: Renaldo N. Battista
Journal: JAMA (1988)

<h3>In Reply.—</h3> We appreciate Mr O'Donnell's interest in our article. We, however, must disagree that limiting the analysis to studies with a control group "severely limits the sample size and makeup" of smoking intervention trials, since two of the largest studies ever carried out<sup>1,2</sup>were randomized trials. Increasing sample size can neither correct for systematic bias in a study design nor eliminate the need for a control group. We are also uncomfortable with the implication that evaluating the effects of therapy diverts resources from treatment. Barnes<sup>3</sup>has noted that worthless surgical procedures persist because of this same argument. We would postulate that careful evaluation actually preserves resources by eliminating the expenditure of resources on worthless or harmful therapies. Our analysis would predict that the smoking cessation program described by Mr O'Donnell<sup>4</sup>would be highly successful. The intervention included group counseling with multiple types of interventions available to
Pediatric Ibuprofen and Leukopenia
Authors: Samuel M. Lesko
Journal: JAMA (1996)

<h3>To the Editor.</h3> —Based on a large clinical trial of pediatric ibuprofen, we reported<sup>1</sup>that hospital admission with a clinical diagnosis of "leukopenia" was more common among children treated with ibuprofen than among children treated with acetaminophen. This association was of borderline statistical significance (<i>P</i>=.04), and a causal relationship was not established. We now report results of a further analysis that includes white blood cell (WBC) count data for all hospitalized study participants. These data were obtained prospectively as part of the Boston University Fever Study; the methods and principal results have been described.<sup>1</sup>Briefly, we conducted a practitioner-based, randomized, double-blind clinical trial to assess the safety of ibuprofen suspension for treatment of fever in children. The study included information on 83 915 children treated for febrile illnesses who received either acetaminophen (12 mg/kg) or ibuprofen in one of two dosages (5 or 10 mg/kg). Information was collected
Circulating clonotypic B cells in classic Hodgkin lymphoma
Authors: Richard J. Jones, Christopher D. Gocke, Yvette L. Kasamon, Carole B. Miller, Brandy Perkins, James P. Barber, Milada S. Vala, Jonathan M. Gerber, Lan L. Gellert, Mark Siedner, M. Victor Lemas, Sarah Brennan, Richard F. Ambinder, William Matsui
Journal: Blood (2009)
ELEVATED LEVELS OF FIBRIN DEGRADATION PRODUCTS IS AN INDEPENDENT PREDICTOR OF INTRAVASCULAR ULTRASOUND–DEFINED FEATURES OF PLAQUE VULNERABILITY IN PATIENTS WITH CORONARY ARTERY DISEASE
Authors: Michel Toni Corban, Parham Eshtehardi, Danny Eapen, Emad Rasoul–Arzrumly, Hatem Al Kassem, Pankaj Manocha, Aalok Patel, Sergey Sikora, Girum Mekonnen, Mohammad Reza Hassanyar, Laurence Sperling, Arshed Quyyumi, Habib Samady
Journal: Journal of the American College of Cardiology (2013)
More use of antihypertensives has cut cardiovascular events in Canada
Authors: B. Kermode-Scott
Journal: BMJ (2009)

A study in Canada has found an association between changes in the use of antihypertensive drugs and a reduction in rates of admission to hospital and deaths from cardiovascular diseases related to hypertension ( Hypertension 2009;53:128, doi:10.1161/hypertensionaha.108.119784).

In 2003 one in seven fewer people died from stroke, one in five from heart failure, and one in 10 from myocardial infarction, than predicted by the annual rates before the introduction of the Canadian Hypertension Education Programme, in 1999.

The diagnosis and treatment of …
Acute Respiratory Failure Associated with Hypophosphatemia
Authors: John H. Newman, Thomas A. Neff, Philip Ziporin
Journal: New England Journal of Medicine (1977)

Hypophosphatemia is now recognized with increasing frequency as a cause of several systemic disorders.1 2 3 4 5 6 7 Routine use of multichannel blood analysis has disclosed this condition in as many as 10 per cent of certain hospital populations.8 , 9 In addition, therapeutic advances of the last several decades have created iatrogenic causes of hypophosphatemia.1 , 2 , 10 , 11 These iatrogenic hypophosphatemias, often profound, have provided the impetus for understanding the multisystem effects of this disorder.2 3 4 5 , 7 , 12 In the two patients described below, ventilatory failure was responsive to inorganic phosphate.Case ReportsCase 1. A 58-year-old alcoholic woman with known chronic obstructive lung disease was admitted to the Neurology Service . . .
Chronic Pain in the Right Iliac Fossa
Authors: S. H. Wass
Journal: BMJ (1955)

<h3>Objectives</h3> To quantitatively assess the early impact of the COVID-19 pandemic on in-person outpatient care utilisation worldwide, as well as across categories of services, types of care and medical specialties. <h3>Design</h3> Rapid review. <h3>Method</h3> A search of MEDLINE and Embase was conducted to identify studies published from 1 January 2020 to 12 February 2021, which quantitatively reported the impact of the COVID-19 pandemic on the amount of outpatient care services delivered (in-person visits, diagnostic/screening procedures and treatments). There was no restriction on the type of medical care (emergency/primary/specialty care) or target population (adult/paediatric). All articles presenting primary data from studies reporting on outpatient care utilisation were included. Studies describing conditions requiring hospitalisation or limited to telehealth services were excluded. <h3>Results</h3> A total of 517 articles reporting 1011 outpatient care utilisation measures in 49 countries worldwide were eligible for inclusion. Of those, 93% focused on the first semester of 2020 (January to June). The reported results showed an almost universal decline in in-person outpatient care utilisation, with a 56% overall median relative decrease. Heterogeneity across countries was high, with median decreases ranging from 10% to 91%. Diagnostic and screening procedures (−63%), as well as in-person visits (−56%), were more affected than treatments (−36%). Emergency care showed a smaller relative decline (−49%) than primary (−60%) and specialty care (−58%). <h3>Conclusions</h3> The provision of in-person outpatient care services has been strongly impacted by the COVID-19 pandemic, but heterogeneously across countries. The long-term population health consequences of the disruption of outpatient care service delivery remain currently unknown and need to be studied. <h3>PROSPERO registration number</h3> CRD42021237366.
Identification of C-C Chemokine Receptor 1 (CCR1) as the Monocyte Hemofiltrate C-C Chemokine (HCC)-1 Receptor
Authors: Chia-Lin Tsou, Ron P. Gladue, Laurie A. Carroll, Tim Paradis, James G. Boyd, Robin T. Nelson, Kuldeep Neote, Israel F. Charo
Journal: The Journal of Experimental Medicine (1998)

Hemofiltrate C-C chemokine (HCC)-1 is a recently cloned C-C chemokine that is structurally similar to macrophage inflammatory protein (MIP)-1α. Unlike most chemokines, it is constitutively secreted by tissues and is present at high concentrations in normal human plasma. Also atypical for chemokines, HCC-1 is reported not to be chemotactic for leukocytes. In this paper, we have investigated the chemokine receptor usage and downstream signaling pathways of HCC-1. Cross-desensitization experiments using THP-1 cells suggested that HCC-1 and MIP-1α activated the same receptor. Experiments using a panel of cloned chemokine receptors revealed that HCC-1 specifically activated C-C chemokine receptor (CCR)1, but not closely related receptors, including CCR5. HCC-1 competed with MIP-1α for binding to CCR1-transfected cells, but with a markedly reduced affinity (IC50 = 93 nM versus 1.3 nM for MIP-1α). Similarly, HCC-1 was less potent than MIP-1α in inducing inhibition of adenylyl cyclase in CCR1-transfected cells. HCC-1 induced chemotaxis of freshly isolated human monocytes, THP-1 cells, and CCR1-transfected cells, and the optimal concentration for cell migration (100 nM) was ∼100-fold lower than that of MIP-1α (1 nM). These data demonstrate that HCC-1 is a chemoattractant and identify CCR1 as a functional HCC-1 receptor on human monocytes.
Tattoos from Insulin Needles
Authors: WALTER B. SHELLEY
Journal: Annals of Internal Medicine (1986)

Brief Reports1 October 1986Tattoos from Insulin NeedlesWALTER B. SHELLEY, M.D., E. DORINDA SHELLEY, M.D., VERONIKA BURMEISTERWALTER B. SHELLEY, M.D.Search for more papers by this author, E. DORINDA SHELLEY, M.D.Search for more papers by this author, VERONIKA BURMEISTERSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-105-4-549 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe 28-gauge disposable sterile hypodermic needle is used by millions of persons needing insulin therapy. The needle, made of stainless steel, is resistant to bending, is ultrasharp with an asymmetric tribevel point, has a surface coated with silicone or polymer, and makes an invasive treatment seem almost noninvasive. Accidental needle sticks would seem to be the only hazard. However, the present case should remind us that technologic advances may lead to new unsuspected hazards.The parents of a 3-year-old diabetic girl noted pinpoint blue spots appearing on her arms, thighs, and buttocks at the sites of certain insulin injections (six...References1. STARCH M. Silicones in hair care products. Drug Cosmetic Industry. 1984;134:38-44. Google Scholar2. LEONGDISNEYGOVE AAD. Spallation and migration of silicone from blood-pump tubing in patients on hemodialysis. N Engl J Med. 1982;306:135-40. CrossrefMedlineGoogle Scholar3. SLATERDURRANT DT. Tattoos: light and transmission electron microscopy studies with x-ray microanalysis. Clin Exp Dermatol. 1984;9:167-73. CrossrefMedlineGoogle Scholar4. ZAPFFE C. Stainless steel. In: McGraw-Hill Encyclopedia of Science and Technology, Volume 13. New York: McGraw-Hill Inc.; 1982:34-9. Google Scholar5. TRIER W Considerations in the choice of surgical needles. Surg Gynecol Obstet. 1979;149:84-94. MedlineGoogle Scholar6. OIKARINENPERKKI VK. A metallurgic and bacteriologic study of disposable injection needles in dental and oral surgery. Proc Finn Dent Soc. 1975;71:147-61. MedlineGoogle Scholar7. GOLDSTEIN N. Complications from tattoos. J Dermatol Surg Oncol. 1979;5:869-78. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Medical College of Ohio Toledo, Ohio College of Medicine at Peoria Peoria, Illinois. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByTattoo removalTattoos as risk factors for transfusion-transmitted diseasesDyschromiasDyschromienEnhancing needle durability by silicone coating of surgical needlesDyschromias 1 October 1986Volume 105, Issue 4Page: 549-550KeywordsDermatologyInsulin Issue Published: 1 October 1986 PDF DownloadLoading ...
Medical treatment in South Africa
Authors: H Bloem
Journal: BMJ (1985)

SIR,-YOU may be one of those who plan your Christmas shopping well in advance, or one who leaves it until the very last minute.But however you set about this annual task I am asking you to spare a thought for those for whom Christmas brings little joy and probably some anxiety.I am referring to those beneficiaries of the Royal Medi- cal Benevolent Fund; some are doctors, some are widows with children, all are in need of our help and may be faced with prospect of having little with which to celebrate Christmas.The object of the Christmas appeal of the Royal Medical Benevolent Fund is to enable us to send financial gifts to our 780 beneficiaries this Christ- mas and also in Christmases to come.These are a special addition to the awards that we make throughout the year.The fund knows through the many letters received how much this little extra means, enabling those less fortunate than our- selves to have at least some joy and warmth at Christmas.
Epoetin Alfa in Patients With Advanced-Stage Hodgkin's Lymphoma: Results of the Randomized Placebo-Controlled GHSG HD15EPO Trial
Authors: Andreas Engert, Andreas Josting, Heinz Haverkamp, Matthias Villalobos, Andreas Lohri, Martin Sökler, Josée Zijlstra, Isrid Sturm, Max S. Topp, Andreas Rank, Thorsten Zenz, Martin Vogelhuber, Lucia Nogova, Peter Borchmann, Michael Fuchs, Hans-Henning Flechtner, Volker Diehl
Journal: Journal of Clinical Oncology (2010)

To determine whether epoetin alfa reduces anemia-related fatigue, improves other aspects of health-related patient-recorded outcomes (PROs), reduces the number of RBC transfusions, and has an impact on freedom from treatment failure (FFTF) and overall survival (OS) in patients with advanced-stage Hodgkin's lymphoma (HL).The prospectively randomized HD15EPO study performed by the German Hodgkin Study Group investigated epoetin alfa administered at doses of 40,000 U weekly during and after chemotherapy (six to eight cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone [BEACOPP]) in a double-blind, placebo-controlled setting. The study accrued 1,379 patients, of whom 1,328 were assessable for safety, 1,303 were assessable for clinical outcome, and 930 were assessable for PROs.PROs were not different in patients receiving placebo or epoetin alfa, both after the end of chemotherapy and 6 months thereafter. There was no difference between patients treated with epoetin alfa or placebo with respect to FFTF and OS. There were also no differences in the numbers of deaths, progressions, relapses, and thromboembolic events. The median number of RBC transfusions was reduced from four per patient in the placebo group to two per patient in the epoetin alfa group (P < .001), with 27.4% of patients needing no RBC transfusion in the placebo group compared with 36.7% of patients in the epoetin alfa group (P < .001).Epoetin alfa administered at 40,000 U weekly parallel to BEACOPP chemotherapy was safe in patients with advanced-stage HL and reduced the number of RBC transfusions but had no impact on fatigue and other PRO domains.
Lupus erythematosus profundus with partial C4 deficiency responding to thalidomide
Authors: N. P. BURROWS, M. J. WALPORT, A. H. HAMMOND, N. DAVEY, R. RUSSELL JONES
Journal: British Journal of Dermatology (1991)

A female patient with disfiguring lupus erythematosus profundus (LEP) from the age of 13 years was found to have an isolated partial C4 deficiency, with reduced levels of both allotypes, C4A and C4B. A genetic basis for the hypocomplementaemia was confirmed by a family study of complement and HLA types which revealed heterozygous null alleles for C4A and C4B in the proband. Marked improvement in her cutaneous lesions occurred with thalidomide.
In vitro and in vivo evaluation of self-mineralization and biocompatibility of injectable, dual-gelling hydrogels for bone tissue engineering
Authors: Tiffany N. Vo, Adam K. Ekenseair, Patrick P. Spicer, Brendan M. Watson, Stephanie N. Tzouanas, Terrence T. Roh, Antonios G. Mikos
Journal: Journal of Controlled Release (2014)
Performance of Serum Cystatin-C Versus Serum Creatinine in Subjects With Type 1 Diabetes
Authors: Martin Buysschaert, Ihab Joudi, Pierre Wallemacq, Michel P. Hermans
Journal: Diabetes Care (2003)

Glomerular filtration rate (GFR) is considered the best marker of renal function, and its estimation using inulin or 51Cr-EDTA is considered the “gold standard.” Such determination is inconvenient and often replaced by an estimate of creatinine clearance (CrCl) derived from the formula of Cockroft and Gault (CG). Serum cystatin-C was recently proposed as a reliable alternative routine marker of GFR in pediatric, adult, and elderly subjects (1–4). Although Dharnidharka et al. (5) thouroughly review the issue of comparing cystatin-C and creatinine in relation to reference GFR measurements, few reports deal with the comparison of serum creatinine and cystatin-C in diabetic patients …
Animal innovation and rationality: Distinguishing productivity from efficiency
Authors: Elias L. Khalil
Journal: Behavioral and Brain Sciences (2007)

Abstract For the authors of the target article, innovations are underdetermined by environmental inducement – but are still adopted in the future. For a productive technology to be adopted, the technology must also be efficient. To be efficient, it must be determined by constraints or environmental inducements. However, this contradicts the authors' notion of “underdetermination.” To make matters clear, we need to distinguish between two kinds of determination: the “source” of the innovation as opposed to “inducement” that makes the organism adopt it in the future.
Predictors of change in the neuropsychological profiles of children with type 1 diabetes 2 years after disease onset.
Authors: E A Northam, P J Anderson, G A Werther, G L Warne, D Andrewes
Journal: Diabetes Care (1999)

To identify type 1 diabetes-related predictors of change in the neuropsychological profiles of children over the first 2 years of the illness.Children (n = 116) aged 3-14 years were assessed soon after diagnosis and re-evaluated 2 years later to examine relationships between illness variables, such as age of onset and metabolic control history, and changes in neuropsychological status over the first 2 years of type 1 diabetes.Illness variables were significant predictors of change in neuropsychological test scores within 2 years of onset of type 1 diabetes. Age of onset of type 1 diabetes predicted negative change on Performance Intelligence Quotient, whereas both recurrent severe hypoglycemia and chronic hyperglycemia were associated with reduced memory and learning capacity.These results suggest that the relationship between metabolic control and neuropsychological risk is nonlinear in that children with either recurrent severe hypoglycemia or chronically elevated blood sugars exhibit negative changes in their neuropsychological profiles. Onset of type 1 diabetes very early in life adds another dimension of risk, particularly affecting the acquisition of visuospatial skills.
White mother given mixed race sperm in IVF loses compensation claim
Authors: C. Dyer
Journal: BMJ (2010)

<h3>Aims</h3> High red cell distribution width (RDW) is a strong prognostic factor in patients with cardiovascular disease. We investigated the association between RDW and incidence of acute coronary events (CEs) and fatal outcome in subjects who subsequently experienced a first CE. <h3>Methods and results</h3> RDW was measured in 26 820 subjects (aged 45–73 years, 61.6% women), without history of myocardial infarction or stroke, who participated in the Malmö Diet and Cancer study during 1991–1996. Cox proportional hazards model was used to analyse the association between RDW and CE. During a mean follow-up of 14 years, 1995 subjects had a first CE, of which 415 subjects died on the same day as the CE (fatal on day 1), another 86 died within 28 days (fatal in 28 days) and 1494 were non-fatal (survived &gt;28 days). After adjustment for risk factors, baseline RDW was significantly associated with incidence of fatal CE (HR 1.82, CI 1.35 to 2.44) but not with non-fatal CE (HR 0.96, CI 0.82 to 1.12). Among all subjects with a CE during follow-up, the proportion who died on day 1 was 13.7%, 18.2%, 22.5% and 26.7%, respectively, for first, second, third and fourth quartiles of RDW. <h3>Conclusions</h3> In this population-based study of subjects without history of CE or stroke, high RDW was associated with increased incidence of fatal CE. No relationship was observed for incidence of non-fatal CE.
ECHOCARDIOGRAPHIC DETERMINANTS OF EARLY MYOCARDIAL RECOVERY IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
Authors: Puja Parikh, Smadar Kort, Kanwar Gill, Usman Tahir, Kathleen Stergiopoulos, Noelle Mann, Howard Novotny, Jordan Katz, Luis Gruberg, Allen Jeremias
Journal: Journal of the American College of Cardiology (2011)